Issue Navigation
-
Original Article
-
148-153
Binding of phenochalasin A, an inhibitor of lipid droplet formation in mouse macrophages, on G-actin
Kobayashi K, Matsuda D, Tomoda H , Ohshiro T
Drug Discov Ther. 2022; 16(4):148-153.
DOI: 10.5582/ddt.2022.01053
-
154-163
Vora U, Vyas V K, Wal P, Saxena B
Drug Discov Ther. 2022; 16(4):154-163.
DOI: 10.5582/ddt.2022.01026
-
164-168
Tosuji E, Inaba Y, Muraoka K, Kunimoto K, Kaminaka C, Yamamoto Y, Jinnin M
Drug Discov Ther. 2022; 16(4):164-168.
DOI: 10.5582/ddt.2022.01046
-
169-176
Qin Q, Nakagami G, Ohashi Y, Dai M, Sanada H, Oe M
Drug Discov Ther. 2022; 16(4):169-176.
DOI: 10.5582/ddt.2022.01050
-
177-184
Harjoko RP, Sobirin MA, Uddin I, Bahrudin U, Maharani N, Herminingsih S, Tsutsui H
Drug Discov Ther. 2022; 16(4):177-184.
DOI: 10.5582/ddt.2022.01020
-
185-190
Prevalence of SARS-CoV-2 antibodies among university athletic club members: A cross-sectional survey
Mori Y, Tanaka M, Kozai H, Hotta K, Aoyama Y, Shigeno Y, Aoike M, Kawamura H, Tsurudome M, Ito M
Drug Discov Ther. 2022; 16(4):185-190.
DOI: 10.5582/ddt.2022.01048
-
191-195
Nakamura K
Drug Discov Ther. 2022; 16(4):191-195.
DOI: 10.5582/ddt.2022.01045
-
196-197
Listing of the neutralizing antibodies amubarvimab and romlusevimab in China: Hopes and impediments
Liu MN, Li W, Lu HZ
Drug Discov Ther. 2022; 16(4):196-197.
DOI: 10.5582/ddt.2022.01055
-
198-199
Effects of raltegravir formulation change on medication adherence and medication errors
Higashino S, Yasu T, Momo K, Kuroda S
Drug Discov Ther. 2022; 16(4):198-199.
DOI: 10.5582/ddt.2022.01054
-
200-203
Portal vein thrombosis as the first presentation of paroxysmal nocturnal hemoglobinuria
Wang R, Guo XZ, Tang YF, Qi XS
Drug Discov Ther. 2022; 16(4):200-203.
DOI: 10.5582/ddt.2022.01033